2025-01-28 20-19-26
Content
- A Urolithin A dose of at least 20.3 mg/kg/day may reduce the progression of Osteoarthritis
References
| Assumptions2 | |
|---|---|
| 2025-01-28 21-34-31 | The progression of knee Osteoarthritis in damicoUrolithinImprovesMitochondrial2022 is similar to that of humans |
| 2025-01-28 21-35-03 | The progression of all types of Osteoarthritis is equally sensitive to treatment by Urolithin A |
| Insights2 | |
|---|---|
| 2025-01-30 15-23-29 | Urolithin A reduces markers of the progression of knee Osteoarthritis at a dose of 250 mg/kg/day, but not 50 mg/kg/day, compared to control when taken for 8 weeks after the induction of experimental Osteoarthritis at 4 months of age |
| 2025-01-29 10-42-32 | A Urolithin A dose of 250 mg/kg/day in a mouse equates to 20.3 mg/kg/day in a human |
| Original Sources2 | Citations |
|---|---|
| usfdaEstimatingMaximumSafe2018 | USFDA. “Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.” FDA, December 1, 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. |
| damicoUrolithinImprovesMitochondrial2022 | D’Amico, Davide, Merissa Olmer, Andréane M. Fouassier, Pamela Valdés, Pénélope A. Andreux, Chris Rinsch, and Martin Lotz. “Urolithin A Improves Mitochondrial Health, Reduces Cartilage Degeneration, and Alleviates Pain in Osteoarthritis.” Aging Cell 21, no. 8 (August 2022): e13662. https://doi.org/10.1111/acel.13662. |